Nature Reviews Drug Discovery, ISSN 1474-1776, 2014, Volume 13, Issue 6, pp. 433 - 444
The liver X receptors (LXRs) are pivotal regulators of lipid homeostasis in mammals. These transcription factors control the expression of a battery of genes...
BINDING CASSETTE TRANSPORTER | BILIARY STEROL SECRETION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | REVERSE CHOLESTEROL TRANSPORT | ALZHEIMERS-DISEASE | LOW-DENSITY-LIPOPROTEIN | PROLIFERATOR-ACTIVATED RECEPTOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | EXPRESSION IN-VITRO | ATHEROSCLEROSIS SUSCEPTIBILITY | LXR-ALPHA | Intestines - drug effects | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - therapeutic use | Intestines - metabolism | Orphan Nuclear Receptors - metabolism | Brain - metabolism | Drugs, Investigational - chemistry | Protein Isoforms - metabolism | Liver - drug effects | Alzheimer Disease - prevention & control | Liver X Receptors | Drug Design | Neurons - metabolism | Hypolipidemic Agents - chemistry | Drug Evaluation, Preclinical | Neurons - drug effects | Hypolipidemic Agents - adverse effects | Nerve Tissue Proteins - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Atherosclerosis - drug therapy | Liver - metabolism | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Hypolipidemic Agents - pharmacology | Nootropic Agents - adverse effects | Nootropic Agents - chemistry | Drug Discovery | Atherosclerosis - metabolism | Brain - drug effects | Nerve Tissue Proteins - metabolism | Orphan Nuclear Receptors - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Alzheimer Disease - metabolism | Lipid Metabolism - drug effects | Hypolipidemic Agents - therapeutic use | Atherosclerosis - prevention & control | Nootropic Agents - pharmacology | Protein Isoforms - antagonists & inhibitors | Care and treatment | Research | Drug discovery | Patient outcomes | Risk factors | Atherosclerosis
BINDING CASSETTE TRANSPORTER | BILIARY STEROL SECRETION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | REVERSE CHOLESTEROL TRANSPORT | ALZHEIMERS-DISEASE | LOW-DENSITY-LIPOPROTEIN | PROLIFERATOR-ACTIVATED RECEPTOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | EXPRESSION IN-VITRO | ATHEROSCLEROSIS SUSCEPTIBILITY | LXR-ALPHA | Intestines - drug effects | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - therapeutic use | Intestines - metabolism | Orphan Nuclear Receptors - metabolism | Brain - metabolism | Drugs, Investigational - chemistry | Protein Isoforms - metabolism | Liver - drug effects | Alzheimer Disease - prevention & control | Liver X Receptors | Drug Design | Neurons - metabolism | Hypolipidemic Agents - chemistry | Drug Evaluation, Preclinical | Neurons - drug effects | Hypolipidemic Agents - adverse effects | Nerve Tissue Proteins - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Atherosclerosis - drug therapy | Liver - metabolism | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Hypolipidemic Agents - pharmacology | Nootropic Agents - adverse effects | Nootropic Agents - chemistry | Drug Discovery | Atherosclerosis - metabolism | Brain - drug effects | Nerve Tissue Proteins - metabolism | Orphan Nuclear Receptors - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Alzheimer Disease - metabolism | Lipid Metabolism - drug effects | Hypolipidemic Agents - therapeutic use | Atherosclerosis - prevention & control | Nootropic Agents - pharmacology | Protein Isoforms - antagonists & inhibitors | Care and treatment | Research | Drug discovery | Patient outcomes | Risk factors | Atherosclerosis
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9911, pp. 60 - 68
Summary Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | DOUBLE-STRANDED-RNA | PLASMA-CHOLESTEROL | METAANALYSIS | CARDIOVASCULAR-DISEASE | MONOCLONAL-ANTIBODY | HYPERCHOLESTEROLEMIA | STATINS | AMG 145 | ATORVASTATIN | Single-Blind Method | Serine Endopeptidases - biosynthesis | Humans | Middle Aged | RNA, Small Interfering - pharmacology | RNA, Small Interfering - adverse effects | Cholesterol, LDL - drug effects | Male | Healthy Volunteers | Proprotein Convertases - genetics | Dose-Response Relationship, Drug | Proprotein Convertases - biosynthesis | RNA Interference | Serine Endopeptidases - blood | Serine Endopeptidases - genetics | Adult | Cholesterol, LDL - blood | Female | Proprotein Convertases - blood | RNA, Small Interfering - administration & dosage | Genetic Therapy - adverse effects | Genetic Therapy - methods | Proprotein Convertase 9 | Enzymes | Research | Gene mutations | Properties | Gene expression | Identification and classification | Medical research | RNA | Low density lipoproteins | Anticholesteremic agents | Clinical trials | Aluminum compounds | Coronary heart disease | Cholesterol | Hypercholesterolemia | Analysis | Medicine, Experimental | Product development | Trans fatty acids | Blood proteins | Studies | Heart | Nanoparticles | Plasma | Nutrition research | Cardiovascular disease | Lipids | Mutation | Drug dosages | Statins
Internal Medicine | MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | DOUBLE-STRANDED-RNA | PLASMA-CHOLESTEROL | METAANALYSIS | CARDIOVASCULAR-DISEASE | MONOCLONAL-ANTIBODY | HYPERCHOLESTEROLEMIA | STATINS | AMG 145 | ATORVASTATIN | Single-Blind Method | Serine Endopeptidases - biosynthesis | Humans | Middle Aged | RNA, Small Interfering - pharmacology | RNA, Small Interfering - adverse effects | Cholesterol, LDL - drug effects | Male | Healthy Volunteers | Proprotein Convertases - genetics | Dose-Response Relationship, Drug | Proprotein Convertases - biosynthesis | RNA Interference | Serine Endopeptidases - blood | Serine Endopeptidases - genetics | Adult | Cholesterol, LDL - blood | Female | Proprotein Convertases - blood | RNA, Small Interfering - administration & dosage | Genetic Therapy - adverse effects | Genetic Therapy - methods | Proprotein Convertase 9 | Enzymes | Research | Gene mutations | Properties | Gene expression | Identification and classification | Medical research | RNA | Low density lipoproteins | Anticholesteremic agents | Clinical trials | Aluminum compounds | Coronary heart disease | Cholesterol | Hypercholesterolemia | Analysis | Medicine, Experimental | Product development | Trans fatty acids | Blood proteins | Studies | Heart | Nanoparticles | Plasma | Nutrition research | Cardiovascular disease | Lipids | Mutation | Drug dosages | Statins
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9784, pp. 2181 - 2192
Summary Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary...
Internal Medicine | UNITED-KINGDOM HEART | DESIGN | METAANALYSIS | REQUIRING PROLONGED OBSERVATION | EFFICACY | CARDIOVASCULAR EVENTS | SAFETY | HEMODIALYSIS | OUTCOMES | UMCG Approved | PARTICIPANTS | MEDICINE, GENERAL & INTERNAL | Confidence Intervals | Simvastatin - adverse effects | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Ezetimibe | Renal Dialysis - methods | Male | Reference Values | Cholesterol, LDL - analysis | Kidney Function Tests | Renal Insufficiency, Chronic - drug therapy | Dose-Response Relationship, Drug | Renal Insufficiency, Chronic - therapy | Renal Dialysis - mortality | Time Factors | Renal Insufficiency, Chronic - mortality | Adult | Female | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Severity of Illness Index | Hypolipidemic Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Simvastatin - administration & dosage | Cholesterol, LDL - drug effects | Treatment Outcome | Azetidines - administration & dosage | Hypolipidemic Agents - administration & dosage | Survival Analysis | Aged | Simvastatin | Low density lipoproteins | Physiological aspects | Drug therapy, Combination | Research | Kidney diseases | Diagnosis | Drug therapy | Health aspects | Studies | Heart failure | Cardiac arrhythmia | Medical imaging | Hospitals | Compliance | Cardiovascular disease | Blood pressure | Family medical history | Cholesterol | Cancer | Mortality | myocardial infarction | cholesterol | councils | Dialysis | medical research | stroke | Kidney | Fast track | Pharmaceutical Sciences | Basic Medicine | PHARMACY | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | FARMACI | Farmaceutiska vetenskaper
Internal Medicine | UNITED-KINGDOM HEART | DESIGN | METAANALYSIS | REQUIRING PROLONGED OBSERVATION | EFFICACY | CARDIOVASCULAR EVENTS | SAFETY | HEMODIALYSIS | OUTCOMES | UMCG Approved | PARTICIPANTS | MEDICINE, GENERAL & INTERNAL | Confidence Intervals | Simvastatin - adverse effects | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Ezetimibe | Renal Dialysis - methods | Male | Reference Values | Cholesterol, LDL - analysis | Kidney Function Tests | Renal Insufficiency, Chronic - drug therapy | Dose-Response Relationship, Drug | Renal Insufficiency, Chronic - therapy | Renal Dialysis - mortality | Time Factors | Renal Insufficiency, Chronic - mortality | Adult | Female | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Severity of Illness Index | Hypolipidemic Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Simvastatin - administration & dosage | Cholesterol, LDL - drug effects | Treatment Outcome | Azetidines - administration & dosage | Hypolipidemic Agents - administration & dosage | Survival Analysis | Aged | Simvastatin | Low density lipoproteins | Physiological aspects | Drug therapy, Combination | Research | Kidney diseases | Diagnosis | Drug therapy | Health aspects | Studies | Heart failure | Cardiac arrhythmia | Medical imaging | Hospitals | Compliance | Cardiovascular disease | Blood pressure | Family medical history | Cholesterol | Cancer | Mortality | myocardial infarction | cholesterol | councils | Dialysis | medical research | stroke | Kidney | Fast track | Pharmaceutical Sciences | Basic Medicine | PHARMACY | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | FARMACI | Farmaceutiska vetenskaper
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2011, Volume 6, Issue 10, p. e25900
Sclerostin is a product of mature osteocytes embedded in mineralised bone and is a negative regulator of bone mass and osteoblast differentiation. While...
MESSENGER-RNA | BONE MORPHOGENETIC PROTEIN | MULTIDISCIPLINARY SCIENCES | HUMAN PRIMARY OSTEOBLASTS | RECEPTOR ACTIVATOR | MECHANICAL STIMULATION | PARATHYROID-HORMONE | CELL-DIFFERENTIATION | WNT | EXPRESSION | KAPPA-B LIGAND | Osteocytes - drug effects | RANK Ligand - metabolism | Apoptosis - drug effects | Humans | Tartrate-Resistant Acid Phosphatase | Osteoclasts - cytology | Cell Differentiation - genetics | Acid Phosphatase - metabolism | Isoenzymes - metabolism | Adult | Osteoblasts - cytology | Bone Morphogenetic Proteins - pharmacology | Osteogenesis - genetics | Cell Survival - drug effects | Calcification, Physiologic - drug effects | Osteocytes - metabolism | Osteoblasts - drug effects | Osteocytes - cytology | Osteogenesis - drug effects | Cells, Cultured | Genetic Markers | Recombinant Proteins - pharmacology | Osteoclasts - metabolism | Gene Expression Regulation - drug effects | RANK Ligand - genetics | Animals | Signal Transduction - drug effects | Cell Differentiation - drug effects | Mice | Osteoblasts - metabolism | Osteoclasts - drug effects | Bones | RNA | Gene expression | Density | Genes | Homeostasis | Osteocytes | Leukocytes (mononuclear) | SOST protein | Biology | Kinases | Osteoprotegerin | Monoculture | Ethics | Genotype & phenotype | Splenocytes | Peripheral blood mononuclear cells | Tumor necrosis factor-TNF | Biocompatibility | TRANCE protein | Discipline | Recombinant | Cytokines | Caspase | Cultures | Bone mass | Osteoblastogenesis | Low density lipoprotein receptors | Osteoclasts | Acid phosphatase (tartrate-resistant) | Bone | Apoptosis
MESSENGER-RNA | BONE MORPHOGENETIC PROTEIN | MULTIDISCIPLINARY SCIENCES | HUMAN PRIMARY OSTEOBLASTS | RECEPTOR ACTIVATOR | MECHANICAL STIMULATION | PARATHYROID-HORMONE | CELL-DIFFERENTIATION | WNT | EXPRESSION | KAPPA-B LIGAND | Osteocytes - drug effects | RANK Ligand - metabolism | Apoptosis - drug effects | Humans | Tartrate-Resistant Acid Phosphatase | Osteoclasts - cytology | Cell Differentiation - genetics | Acid Phosphatase - metabolism | Isoenzymes - metabolism | Adult | Osteoblasts - cytology | Bone Morphogenetic Proteins - pharmacology | Osteogenesis - genetics | Cell Survival - drug effects | Calcification, Physiologic - drug effects | Osteocytes - metabolism | Osteoblasts - drug effects | Osteocytes - cytology | Osteogenesis - drug effects | Cells, Cultured | Genetic Markers | Recombinant Proteins - pharmacology | Osteoclasts - metabolism | Gene Expression Regulation - drug effects | RANK Ligand - genetics | Animals | Signal Transduction - drug effects | Cell Differentiation - drug effects | Mice | Osteoblasts - metabolism | Osteoclasts - drug effects | Bones | RNA | Gene expression | Density | Genes | Homeostasis | Osteocytes | Leukocytes (mononuclear) | SOST protein | Biology | Kinases | Osteoprotegerin | Monoculture | Ethics | Genotype & phenotype | Splenocytes | Peripheral blood mononuclear cells | Tumor necrosis factor-TNF | Biocompatibility | TRANCE protein | Discipline | Recombinant | Cytokines | Caspase | Cultures | Bone mass | Osteoblastogenesis | Low density lipoprotein receptors | Osteoclasts | Acid phosphatase (tartrate-resistant) | Bone | Apoptosis
Journal Article